1. Home
  2. TENX vs PSTV Comparison

TENX vs PSTV Comparison

Compare TENX & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$12.82

Market Cap

56.2M

Sector

Health Care

ML Signal

HOLD

Logo PLUS THERAPEUTICS Inc.

PSTV

PLUS THERAPEUTICS Inc.

HOLD

Current Price

$0.26

Market Cap

46.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TENX
PSTV
Founded
1967
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
56.2M
46.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TENX
PSTV
Price
$12.82
$0.26
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$22.50
$6.75
AVG Volume (30 Days)
294.1K
20.0M
Earning Date
03-24-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,258,000.00
Revenue This Year
N/A
$1.73
Revenue Next Year
N/A
$12.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.63
$0.16
52 Week High
$18.38
$2.31

Technical Indicators

Market Signals
Indicator
TENX
PSTV
Relative Strength Index (RSI) 46.69 34.52
Support Level $12.53 $0.25
Resistance Level $14.08 $0.28
Average True Range (ATR) 0.95 0.02
MACD -0.23 0.01
Stochastic Oscillator 17.74 71.52

Price Performance

Historical Comparison
TENX
PSTV

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

About PSTV PLUS THERAPEUTICS Inc.

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Share on Social Networks: